OBJECTIVE: To determine the diagnostic value of CSF amyloid beta(1-42) (Abeta42), CSF total tau, and CSF tau phosphorylated at threonine-181 (Ptau-181) in early-onset Alzheimer disease (EAD) vs frontotemporal lobar degeneration (FTLD). METHODS: Levels of Abeta42, total tau, and Ptau-181 in CSF were measured using commercially available ELISA in 47 EAD patients, 28 FTLD patients, and 21 nondemented control subjects. RESULTS: CSF Abeta42 was significantly lower and CSF total tau and CSF Ptau-181 significantly higher in EAD patients than FTLD patients and control subjects. There was an increase in diagnostic accuracy for CSF Ptau-181 vs CSF total tau (p = 0.067). Combining low CSF Abeta42 and high CSF Ptau-181 allowed EAD patients to be distinguished from FTLD patients with a sensitivity of 72% and a specificity of 93%. Logistic regression analysis with CSF Abeta42 and CSF Ptau-181 as independent continuous variables resulted in correct classification of 46 of 47 (98%) EAD patients and 23 of 28 (82%) FTLD patients. The diagnostic accuracy for EAD was independent of gender, disease duration, and disease severity. CONCLUSION: The combination of CSF Abeta42 and CSF Ptau-181 may help in differentiating EAD from FTLD.
OBJECTIVE: To determine the diagnostic value of CSF amyloid beta(1-42) (Abeta42), CSF total tau, and CSFtau phosphorylated at threonine-181 (Ptau-181) in early-onset Alzheimer disease (EAD) vs frontotemporal lobar degeneration (FTLD). METHODS: Levels of Abeta42, total tau, and Ptau-181 in CSF were measured using commercially available ELISA in 47 EADpatients, 28 FTLDpatients, and 21 nondemented control subjects. RESULTS:CSF Abeta42 was significantly lower and CSF total tau and CSFPtau-181 significantly higher in EADpatients than FTLDpatients and control subjects. There was an increase in diagnostic accuracy for CSFPtau-181 vs CSF total tau (p = 0.067). Combining low CSF Abeta42 and high CSFPtau-181 allowed EADpatients to be distinguished from FTLDpatients with a sensitivity of 72% and a specificity of 93%. Logistic regression analysis with CSF Abeta42 and CSFPtau-181 as independent continuous variables resulted in correct classification of 46 of 47 (98%) EADpatients and 23 of 28 (82%) FTLDpatients. The diagnostic accuracy for EAD was independent of gender, disease duration, and disease severity. CONCLUSION: The combination of CSF Abeta42 and CSFPtau-181 may help in differentiating EAD from FTLD.
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-02-11 Impact factor: 17.088
Authors: H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer Journal: J Neural Transm (Vienna) Date: 2006-06-01 Impact factor: 3.575